Bessemer Group Inc. Sells 29,560 Shares of IDEXX Laboratories, Inc. $IDXX

Bessemer Group Inc. decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 352,268 shares of the company’s stock after selling 29,560 shares during the quarter. Bessemer Group Inc. owned about 0.44% of IDEXX Laboratories worth $225,061,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of IDXX. WealthCollab LLC purchased a new stake in IDEXX Laboratories in the second quarter worth $30,000. J.Safra Asset Management Corp purchased a new position in IDEXX Laboratories during the 3rd quarter valued at about $31,000. Armstrong Advisory Group Inc. raised its holdings in shares of IDEXX Laboratories by 55.9% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after purchasing an additional 19 shares in the last quarter. Salomon & Ludwin LLC purchased a new stake in shares of IDEXX Laboratories in the 3rd quarter worth approximately $35,000. Finally, Greykasell Wealth Strategies Inc. bought a new position in shares of IDEXX Laboratories during the third quarter valued at approximately $35,000. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of recent research reports. JPMorgan Chase & Co. boosted their price objective on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Leerink Partners set a $785.00 target price on IDEXX Laboratories in a research note on Monday, November 3rd. Barclays began coverage on shares of IDEXX Laboratories in a research report on Monday, December 8th. They set an “overweight” rating and a $850.00 price target for the company. Jefferies Financial Group restated a “buy” rating and issued a $830.00 price target on shares of IDEXX Laboratories in a report on Tuesday, November 4th. Finally, Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

Insider Activity at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the sale, the executive vice president owned 21,149 shares in the company, valued at $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Trading Up 1.6%

NASDAQ:IDXX opened at $642.94 on Thursday. The company has a market capitalization of $51.34 billion, a P/E ratio of 49.19, a PEG ratio of 3.86 and a beta of 1.67. The company has a current ratio of 1.23, a quick ratio of 0.87 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The firm has a fifty day simple moving average of $698.15 and a 200-day simple moving average of $663.33.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the business posted $2.53 EPS. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.